secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001104659-24-043233
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 5.03, 2.01, 3.02, 3.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconova merges with Trawsfynydd, changes name to Traws Pharma, raises $14M PIPE
--------------------------------------------------------------------------------

- Acquired Trawsfynydd in reverse merger; issued 3,549,538 common shares and 10,359 Series C preferred shares to Trawsfynydd stockholders.
- Company renamed Traws Pharma, Inc.; ticker changed to TRAW on Nasdaq.
- New leadership: Werner Cautreels appointed CEO; Iain Dukes Executive Chairman; Nikolay Savchuk COO; Robert Redfield CMO; C. David Pauza CSO Virology.
- Concurrent $14M PIPE financing: sold 496,935 common shares and 1,578 Series C preferred shares to Torrey Pines affiliate and OrbiMed.
- CVRs issued to all common shareholders as of April 15, 2024, entitling to 43.7% of net proceeds from sale of rigosertib/narazaciclib or 6.24% of net sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/0001104659-24-043233-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465924043233/tm2410784d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-043233

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer